Benjamin Z Leder
Overview
Explore the profile of Benjamin Z Leder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2430
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McClung M, Betah D, Leder B, Kendler D, Oates M, Timoshanko J, et al.
J Bone Miner Res
. 2024 Dec;
40(2):193-200.
PMID: 39656908
Bone mineral density (BMD) is only one of several bone strength determinants affected by osteoporosis therapies. Trabecular Bone Score (TBS), a gray-level texture index determined from lumbar spine (LS) dual-X-ray...
2.
Kobelski M, Ramchand S, Tsai J, Leder B, Demay M
Endocrinology
. 2024 Oct;
165(12).
PMID: 39445778
Aging of the general population has led to a substantial increase in the prevalence of osteoporosis over the past decades. While there are effective pharmacological agents that increase bone formation,...
3.
Sun X, Bolster M, Leder B, Fan W
J Clin Endocrinol Metab
. 2024 Oct;
PMID: 39391899
Context: Patients with osteoporosis and advanced chronic kidney disease (CKD) are at increased risk for hypocalcemia when initiating denosumab. It remains unclear if subsequent doses of denosumab pose similar hypocalcemia...
4.
Tsai J, Jordan M, Lee H, Leder B
Osteoporos Int
. 2024 Aug;
35(12):2225-2230.
PMID: 39112628
Background: When denosumab is discontinued, antiresorptive therapy is critical to attenuate high-turnover bone loss. The ideal choice and duration of antiresorptive therapy are not yet defined, however. In the Comparison...
5.
Fan W, Sun X, Leder B, Lee H, Ly T, Pu C, et al.
J Bone Miner Res
. 2024 Jul;
39(8):1061-1070.
PMID: 38952014
Inpatient zoledronic acid (IP-ZA) administered during the initial fracture hospitalization significantly improves the osteoporosis treatment rate. Clinical outcomes of IP-ZA after hip fracture remain uncertain. Here we report a cohort...
6.
Sun X, Leder B, Bolster M, Ly T, Franco-Garcia E, Pu C, et al.
J Endocr Soc
. 2024 Mar;
8(5):bvae050.
PMID: 38550278
Context: Addressing vitamin D deficiency (VDD) is important for fracture secondary prevention. Objectives: To explore the function of a fracture liaison service (FLS) to address VDD. Design Setting And Patients:...
7.
Cosman F, Langdahl B, Leder B
Endocr Pract
. 2024 Feb;
30(5):490-496.
PMID: 38311211
Background: Osteoporosis is a chronic progressive disease that requires lifelong monitoring and treatment. Sequencing from one treatment to another at different ages and stages of disease is an approach that...
8.
Ramchand S, Tsai J, Lee H, Sassana-Khadka G, Jordan M, Ryan S, et al.
Osteoporos Int
. 2023 Nov;
35(2):371.
PMID: 37940698
No abstract available.
9.
Ramchand S, Tsai J, Lee H, Sassana-Khadka G, Jordan M, Ryan S, et al.
Osteoporos Int
. 2023 Oct;
35(2):255-263.
PMID: 37798320
Purpose: The aim of this study was to evaluate the comparative efficacy of alendronate and the SERM, raloxifene, in preventing the post-denosumab high-turnover bone loss. Methods: We conducted an open-label...
10.
Ramchand S, Leder B
J Clin Endocrinol Metab
. 2023 Aug;
109(2):303-311.
PMID: 37610985
Osteoporosis is a chronic condition characterized by decreased bone mass, loss of skeletal integrity, and increased susceptibility to fracture. Drugs used to treat osteoporosis can be classified as those that...